Pharma Exclusives Pressreleases
AbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025
Wednesday, March 26, 2025AbbVie today announced that new data from its early oncology research will be showcased across multiple presentations at the upcoming American Association of Cancer Research AACR Annual Meeting April
Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Tuesday, March 25, 2025Merck known as MSD outside of the United States and Canada and Jiangsu Hengrui Pharmaceuticals Co Ltd Hengrui Pharma a global pharmaceutical company focused on scientific and technological innovation
Thermo Fisher Scientific Introduces the Vulcan™ Automated Lab to Transform Semiconductor Analysis
Tuesday, March 18, 2025Thermo Fisher Scientific Inc the world leader in serving science today announced the launch of the Thermo Scientific Vulcan Automated Lab a groundbreaking solution designed to drive a new era of process development and control in semiconductor
GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
Monday, March 17, 2025GRI Bio Inc a biotechnology company advancing an innovative pipeline of Natural Killer T NKT cell modulators for the treatment of inflammatory fibrotic and autoimmune diseases has reported its financial results for the fiscal year ended December an...
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
Tuesday, March 11, 2025Biogen Inc announced the initiation of dosing in the global clinical study TRANSCEND The Phase study will evaluate the efficacy and safety of the investigational drug felzartamab compared to placebo in adult kidney transplant recipients diagnosed w...
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
Tuesday, March 11, 2025Arvinas Inc and Pfizer Inc announced positive topline results from the Phase VERITAC clinical trial NCT evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptorpositive human epidermal growth factor receptor negative...
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer’s Disease in Australia
Monday, March 03, 2025Eisai Co Ltd and Biogen Inc announced that the Therapeutic Goods Administration TGA of Australia has confirmed the initial decision to decline the approval of humanized antisoluble aggregated amyloidbeta AB monoclonal antibody lecanemab generic name...
Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules
Monday, March 03, 2025Eton Pharmaceuticals Inc an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases today announced that it has launched Galzin zinc acetate capsules Galzin is FDAapproved for the maintenance treatment...
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis
Friday, February 28, 2025AbbVietoday announced that the European Medicines Agencys Committee for Medicinal Products for Human Use CHMP adopted a positive opinion recommending the approval of upadacitinib RINVOQ mg once daily for the treatment of adult patients
FDA Prioritises Review of Merck’s Application for KEYTRUDA® (pembrolizumab) with Standard Treatment for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma
Tuesday, February 25, 2025Merck NYSE MRK known as MSD outside of the United States and Canada today announced the US Food and Drug Administration FDA has accepted for priority review a new supplemental Biologics License Application sBLA seeking approval for KEYTRUDApembrolizu...
